



GOG PARTNERS CONNECTION

A Quarterly Newsletter
From GOG Partners, A GOG Foundation Program

The GOG Foundation, Inc. has one mission that is dedicated to transforming the standard of care in gynecologic oncology.

A Message from Larry J. Copeland, MD President, The GOG Foundation, Inc.

The upcoming July 2023 NRG Semiannual Meeting marks my last meeting as President of The GOG Foundation, Inc. (GOG). Reflecting on my career and the past 50 years that I've had the honor to serve in many different roles as student, physician, colleague, leader, author, principal investigator, mentor, and friend, I want to take the time to express my sincere gratitude for everyone's extraordinary efforts to help find a cure to women's cancer.



Our commitment to transform the standard of care is exceptional, guided by our organizational culture and strong collaboration with our colleagues and pharmaceutical partners. When the results of a clinical trial are positive those results reenergize our efforts for more and greater success. I have no doubt that we are now curing patients secondary to our 50 plus years of conducting clinical trials. But each of us, when talking with our patient who is transitioning to comfort care, must have a gut check to drive forward to be able to treat tomorrow's patient more successfully than today's patient. Every day we must engage in the process of increasing curative therapy for patients with gynecologic malignancies.

I often find myself thinking about the many challenges we face in our clinics as physicians and with our team of leaders. What the GOG set out to do is to help find new opportunities, new drugs, new combination therapies that can treat patients facing gynecologic cancers and for your efforts and incredible work over the years, I want to share my heartfelt appreciation.

THANK YOU...to the GOG Sites that have enrolled 5,085 patients on to 47 clinical trials throughout my leadership as President. Your efforts allowed us to assist our pharmaceutical partners to gain FDA Approval on 11 studies and find new options to treat gynecologic cancers. Your leadership as principal investigators and thought leaders have

allowed this organization to fulfill our mission. By enrolling patients on trials, you contribute to the potential for patients to live better and longer lives.

THANK YOU...to our patients and families of the patients who trust our guidance and enroll on our trials. Our research, development of science, and understanding of new treatment options could not happen without you. You are helping advance gynecologic oncology and giving hope and promise for tomorrow.

THANK YOU...To the entire GOG Staff, who work to support an incredibly busy leadership team, GOG sites, patients, and endless ideas to continue to build the organization. These individuals are the backbone of our success, constantly working outside normal business hours to keep up with the pace of our business and ensure that messages are answered to bring new patients and sites to our clinical trials.

THANK YOU...to our global collaborators. The ENGOT leadership, colleagues in Brazil, Canada, Japan, South Korea and those that work alongside us throughout the world to ensure new and effective treatments have a global reach.

THANK YOU...to our industry supporters. Your engagement with the physician leadership and partnership to help find cures are extraordinary.

THANK YOU...to the organizations with which we are associated: IGCS, SGO, ESGO, ESMO, ASCO. It is an honor to share our clinical trial results at your meetings. The scientific data we share are all a presentation of hope. Our groups all sitting alongside one another, supporting our friends, colleagues, and partners always with such pride to share data and updates from our clinical trials.

THANK YOU...to the GOG Foundation's board of directors, Dr. Robert Mannel, Dr. Carol Aghajanian, Dr. Paul Disilvestro, Dr. David Mutch, Dr. Thomas Herzog, Dr. Bradley Monk, Dr. Robert Coleman, Dr. Leslie Randall, Dr. Angeles Alvarez-Secord, Dr. Alex Olawaiye, Dr. David O'Malley, Dr. Brian Slomovitz, Dr. Tashanna Myers and Dr. Shannon Westin for your efforts and leadership during the transition of the cooperative groups, maneuvering through a global pandemic. Your thoughtful guidance is what continues to make this organization great and your ability to change and grow is what makes GOG GREAT.

THANK YOU...to The GOG Partner's Leadership. Dr. Robert Coleman, Dr. Bradley Monk, Dr. Thomas Herzog, Dr. Kathleen Moore, Dr. David O'Malley, Dr. Leslie Randall, Dr. Brian Slomovitz, Dr. Bhavana Pothuri, Dr. Ramez Eskander. The development of this team and the expansion of the GOG Partners portfolio is one of my greatest professional accomplishments and I am forever grateful for the incredible commitment and culture you have created.

And finally, THANK YOU to my Family for your unwavering support and encouragement. My amazing mentor and wife, Lisa, my daughters Laura Lee, Nicole and Kelly and their families.

It is a privilege to have served my profession since graduation from medical school, 50

years in May 2023. It has been an incredible honor to serve The GOG Foundation since 1989, and as President for the past 8 years. I transition away from my role as President with my sincere gratitude to so many and with hope for the future. I will, and always will, be here to support the mission to transform the standard of care in women's cancer and this wonderful organization. I am proud to have played a small role in creating hope for tomorrow.

Best,
Cope

IGCS & The GOG Foundation Partner for Education

The GOG Foundation, Inc. (GOG) and IGCS are pleased to announce a strategic partnership whereby the GOG will be the preferred educational provider for Industry Supported Symposia (ISS) starting at the 2023 IGCS Annual Global Meeting in Seoul.

Together, we will work synergistically to determine the most relevant topics for symposia each year and the optimal delivery method.



IGCS President, Dr. Keiichi Fujiwara said, "This partnership is a perfect opportunity to use the strengths of the GOG's clinical research expertise to educate IGCS members and the thousands of delegates who rely on the IGCS Annual Global Meeting for the latest information in gynecologic cancer care."

[Click here](#) to learn more about our partnership with IGCS

FEATURED CLINICAL TRIALS

GOG-3026 PRESS RELEASE

Philadelphia, PA, USA, March 25, 2023, The GOG Foundation, Inc. (GOG) announced positive results from an investigator-initiated phase II trial, sponsored by the GOG, investigating the combination of ribociclib and letrozole in patients with recurrent low-grade serous ovarian cancer (LGSOC) (GOG-3026). The results were presented at The Society of Gynecologic Oncology's 2023 Annual Meeting on Women's Cancer [™] in Tampa, Florida.

Ribociclib and letrozole combination is active in patients with advanced or recurrent LGSOC: Phase II trial results:

- Ribociclib and letrozole is an active combination in LGSOC.
- ORR, PFS, DOR compare favorably to most active agents previously investigated.

In this trial, the reported response rate was 23%, the progression-free survival 19.1 months, and the duration of response of 19.1 months. Sixty-four percent of evaluable

patients experienced a reduction in target tumor size.

“These results are promising. Women with this disease have limited treatment options. The progression-free survival and duration of response are both 6 months greater than what we have observed with the current standard treatments,” stated Brian Slomovitz, MD, Professor of Obstetrics/Gynecology and Division Director at Mount Sinai Medical Center in Miami Beach, Florida and the Principal Investigator for this trial.



[Click here](#) to view the press release.

ENGOT-EN6-NSGO/GOG-3031/RUBY TRIAL

The new standard of care in advanced/recurrent endometrial cancer

ENGOT, NSGO-CTU & GOG-Foundation proudly announce the ground-breaking results of ENGOT-EN6-NSGO/GOG-3031/RUBY trial.

The results reveal improvement in overall survival at 24 months in whole study population from 56% (CP+placebo) to 71.3% (CP+dostarlimab). “Although these are interim data, we believe they are robust and will be confirmed with longer follow-up,” said Mansoor R. Mirza.

The trial was presented on 27th of March 2023 through ESMO’s Virtual Plenary and at the Society of Gynecologic Oncology’s (SGO) Annual Meeting on Women’s Cancer. The trial’s results were simultaneously published in the New England Journal of Medicine, demonstrate unprecedented improvement in Progression-Free Survival and Overall Survival of patients with primary advanced or recurrent endometrial cancer (EC) when treated with dostarlimab in combination with standard of care carboplatin/paclitaxel (CP) followed by dostarlimab monotherapy compared to chemotherapy alone.

“Carboplatin/paclitaxel is the standard of care for first-line treatment of primary advanced or recurrent endometrial cancer; however long-term outcomes remain poor, with median overall survival of less than 3 years. Anti-PD-1 based therapy has transformed the management of endometrial cancer post-platinum chemotherapy, however, advances in first-line systemic treatment were urgently needed”, says study chair Mansoor R. Mirza (NSGO-CTU). “These results are unprecedented and shall considerably improve the outcome of our patients.”



[Click here](#) to view the press release.

Demonstrates Improved PFS Outcomes with the Addition of Pembrolizumab to Chemotherapy for Women with Advanced or Recurrent Endometrial Cancer

Protocol-specified first interim analysis results from the Phase III NRG-GY018 clinical trial comparing pembrolizumab combined with standard of care chemotherapy followed by maintenance pembrolizumab to placebo combined with chemotherapy followed by placebo indicated that patients with stage III-IV or recurrent endometrial cancer who received pembrolizumab exhibited improved progression-free survival outcomes. These findings were presented as a late-breaking abstract at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer and are also simultaneously being published in the [New England Journal of Medicine](#).

NRG-GY018 accrued 816 women with stage III-IV or recurrent endometrial cancer, with two defined patient cohorts: mismatch repair deficient (dMMR) and mismatch repair proficient (pMMR). Patients on the trial were randomly assigned to receive pembrolizumab combined with carboplatin and paclitaxel (for a planned six, 3-week cycles), followed by pembrolizumab maintenance (for up to fourteen, 6-week cycles) on Arm A or placebo combined with carboplatin and paclitaxel, followed by placebo maintenance on Arm B.

In the pMMR cohort of 591 evaluable patients, after a median follow-up of 7.9 months, the pembrolizumab regimen significantly reduced the risk of disease progression or death by 46% (HR=0.54 [95% CI, 0.41-0.71]; $p<0.00001$) compared to chemotherapy alone; median PFS was 13.1 months (95% CI, 10.5-18.8) for the pembrolizumab regimen versus 8.7 months (95% CI, 8.4-10.7) for chemotherapy alone. In the dMMR cohort of 225 evaluable patients, after a median follow-up of 12 months, the pembrolizumab regimen significantly reduced the risk of disease progression or death by 70% (HR=0.30 [95% CI, 0.19-0.48]; $p<0.00001$) compared to chemotherapy alone; median PFS was not reached (95% CI, 30.6-NR) for the pembrolizumab regimen versus 7.6 months (95% CI, 6.4-9.9) for chemotherapy alone.

"Patients with advanced stage or recurrent endometrial cancer, the most common type of gynecologic cancer in the U.S., face a poor prognosis with limited treatment options," stated Ramez Eskander, MD, of the University of California San Diego Moores Cancer Center and the Principal Investigator of the NRG-GY018 trial. "In this study, pembrolizumab in combination with carboplatin and paclitaxel resulted in a statistically significant and clinically meaningful improvement in PFS in both the dMMR and pMMR study populations. Future analysis will examine the secondary endpoints of this study, including overall survival and quality of life outcomes."



[Click here](#) to view the press release.

SPECIAL RECOGNITION

PI Perspective: The Journey of NRG-GY018

Written by NRG-GY018 Principal Investigator, Ramez Eskander, MD

Unlike other solid malignancies, there has been limited improvement in survival for women with metastatic or recurrent endometrial cancer (EC) over the last 4 decades. NRG GY018 was designed to determine if the addition of the immune checkpoint inhibitor, pembrolizumab, to carboplatin and paclitaxel followed by pembrolizumab maintenance would result in improved survival. Based on prior trials in alternate solid tumors, most notably colorectal cancer, it was anticipated that a more robust improvement would be identified in the mismatch repair deficient (dMMR) EC population.

[Click here](#) to read the full article.

Research Recap: NRG at SGO 2023

Study Identifies Two Promising Molecular Targets for Drug Development in Recurrent and Metastatic Cervical Cancer



[Click here](#) to read the full Press Release

The Utilization of Atezolizumab as a Primer for Chemoradiation Results in Promising Immune System Alterations for Women with Locally Advanced Cervical Cancer

[Click here](#) to read the full Press Release

The Addition of Gemcitabine with Cisplatin and Intensity-Modulated Radiation Therapy Improves Outcomes for Women with Locally Advanced Vulvar Cancer

[Click here](#) to read the full Press Release

MARY “DICEY” SCROGGINS TRAVEL FUND REQUEST FOR APPLICATIONS

Mary “Dicey” Jackson Scroggins, a long-time patient advocate and mentor, passed away on August 1, 2022.



Dicey was a 26-year ovarian cancer survivor and health activist who made a significant impact supporting diversity, equality and inclusion in the development of our clinical trials aimed at transforming the standard of care in gynecologic oncology. Mary served on the Board of Directors for NRG Oncology from 2014 – 2019. She was the Chair of The GOG Foundation, Inc. (Gynecologic Oncology Group legacy) Patient Advocate Committee from 2006-2014 when she then transitioned to serve as Chair of the NRG Oncology Patient

Advocate Committee from 2014-2019. For many years Dicey attended The GOG Foundation Board of Directors as an ex officio member representing the patient voice and guiding the GOG to better serve patients.

To honor and continue Dicey's legacy, the GOG will continue accepting applications for the Mary "Dicey" Scroggins Travel Fund.

Award recipients will receive travel reimbursement to attend the NRG Oncology Semi-Annual meetings and the GOG Foundation, Inc. meetings being held July 20-22, 2023 in Philadelphia, PA and February 15-17, 2024 in Orlando, FL.

Application Deadline is May 31, 2023.

[Submit Application](#)

UPCOMING INDUSTRY MEETINGS

ASCO Annual Meeting



The 2023 ASCO Annual Meeting will be held on **June 2 - 6, 2023** in Chicago, IL, at the **McCormick Place Convention Center**. This year's meeting is only available in person.

Join fellow oncology professionals at the 2023 ASCO Annual Meeting – a unique and unparalleled opportunity to connect with one of the largest, most diverse audiences in global cancer care.

[Click Here](#) for more information on the ASCO Annual Meeting.

WAGO Annual Meeting



The 2023 WAGO Annual Meeting will be held on **June 14 - 17 2023** in Monterey, CA at the **Hyatt Regency Monterey Hotel & Spa**.

[Click Here](#) for more information on the WAGO Annual Meeting.

The GOG Highlight Reel - June 2023



The GOG Foundation, Inc. and GOG Partners

welcomes gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to attend the live broadcast of **The GOG Highlight Reel** educational program on **Saturday, June 17, 2023 from 12:30 pm –3:30 pm PT**.

This installment of the GOG Highlight Reel will be presented both virtually and in person from Monterey, California following the WAGO 2023 Annual Meeting.

[Click here](#) to register.

IGCS 2023 Annual Global Meeting



The IGCS 2022 Annual Global Meeting will be held **November 5 – 7, 2023 in Seoul, South Korea.**

Abstract and Surgical Film submission is open. **Deadline is May 8th.** Submit your research to the largest international meeting dedicated to women's cancers.


[Click here to submit an abstract](#)

[View the abstract topics here](#)

[View the Program Committee here](#)

IGCS 2023 Scientific Co-Chairs

- Suk-Joon Chang, MD, PhD Korea
- Christina Fotopoulou, MD, PhD UK



ON DEMAND EDUCATION

The GOG Foundation, Inc. is thrilled to share the following Industry Supported Symposium Enduring Educational Materials from the 2023 SGO Annual Meeting on Women's Cancer[®] and the 2022 IGCS Annual Global Meeting.

Click the session title below to view these exciting sessions available today!

2023 SGO Annual Meeting on Women's Cancer[®]

- [Novel combinations, biomarkers and immune modulators to overcome platinum resistance in recurrent ovarian cancer \(PROC\)](#)
- [Patient Management: Engaging the care team to provide new treatment opportunities with an ADC in recurrent metastatic cervical cancer](#)

2022 IGCS Annual Global Meeting

- [Antibody Drug Conjugates as an Exciting New Drug Class](#)
- [It takes a village: Interdisciplinary management of patients with advanced cervical](#)

- [Platinum Sensitive Ovarian Cancer: Unmet Medical Need Beyond PARP Inhibitors](#)

CLINICAL TRIALS

The GOG Partners Program is currently recruiting for 21 clinical trials

- **14 Ovary**
- **1 Cervix**
- **6 Endometrium**



To search active trials visit our website by clicking Clinical Trials button below.

Clinical Trials

Roster Management Announcement

GOG Partners is pleased to announce an update to the GOG Partners Portal (<https://partners.gog.org/>) for sites to better maintain their rosters. The purpose of this enhancement is to allow for management of institution and person data by individuals within the site.

The benefits of these updates include:

- Ownership of your site's roster.
- Requests to add/remove personnel are not delayed and can be done immediately.
- To retire paper roster form.
- Easier and more reliable communications.
- Streamline interest/feasibility (upcoming).

For instruction on who can manage and how to maintain institution and person data, instructions can be accessed through the following link: [Roster Management Instructions](#)

The GOG Partners Regulatory Department is available for questions and trainings. Please contact them at GOGRegulatory@gog.org.

PHILANTHROPY

New Horizons Gynecologic Cancer Research Fund



The New Horizons Gynecologic Cancer Research Fund is the philanthropic arm for The GOG Foundation, Inc. Donations allow the GOG to enrich efforts to develop and deliver essential research tools needed to further clinical trial development and translational research programs.

Donations from individuals, corporations, and foundations directly fund the GOG educational and research initiatives. Together, we collaborate with industry to find new treatments, and more effective prevention while promoting excellence in scientific research in the field of gynecologic malignancies.

Each donation received will go directly to provide:

- Much needed resources to effectively work towards the prevention and treatment of gynecologic malignancies
- Accessible research funding
- Ability to mentor New Investigators through fellowship awards
- Opportunity to raise public awareness through education and research
- Translational medicine initiatives across the disease committees

Click the Support Our Mission button below to make a donation today!

**Support Our
Mission**

LET'S GET SOCIAL



What GOG Means to Me

“ ”

GOG means research success and amazing people. GOG runs trials that provide novel effective treatments for patients with gynecologic malignancies. GOG is inclusive in mentoring our next generation of clinical trialists to be the best

“ ”

Thomas J. Herzog, MD
GOG Partners Associate Director
Clinical Director
Paul & Carolyn Flory Professor in Gynecologic Oncology
University of Cincinnati

GOG FOUNDATION™
Transforming the standard of care

GOG PARTNERS
A GOG Foundation Program

What GOG Means to ME

The GOG Foundation, Inc. launched a “What GOG Means to ME” social media campaign and we would like you to participate.

As a participant in this campaign, you will be highlighted on our social media feeds (Twitter, Instagram, LinkedIn and Facebook). If you would like to participate, please email Lindsey Moeller at lmoeller@gog.org and include the following



Dana Chase
Arizona Center for Cancer Care

GOG FOUNDATION
SOCIAL AGENT

THE GOG FOUNDATION, INC
DINNER MEETING
JANUARY 26, 2023

Become a GOG Social Media Agent

The GOG Foundation is looking for members that are savvy with social media to become GOG Social Media Agents! Throughout the year our communications staff will invite our agents to participate in social media campaigns for meetings, education and special events. If you are interested in becoming a GOG Social Media Agent, please email Lindsey Moeller at lmoeller@gog.org and include the following information:

information:

- **Quote:** No more than 35 words indicating what GOG means to you, examples can include: research, clinical trials, networking.
- **Current Headshot** (Jpg or PNG format)
- **Current Title/Role**
- **Institution**
- **Social Tags:** Please provide how we can find you on each of the social platforms so we can tag you when we post.
- **Current Headshot** (Jpg or PNG format)
- **Current Title/Role**
- **Institution**
- **Social Tags:** Please provide how we can find you on each of the social platforms so we can tag you when we post.



How Can We Help?

The GOG Partners Connection Quarterly Newsletter is produced by the GOG Foundation Communications Committee.

Please contact us at info@gog.org with any questions or suggestions regarding future content.